Loading clinical trials...

Platelet Rich Plasma (PRP) in Total Knee Replacement | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Platelet Rich Plasma (PRP) in Total Knee Replacement

Platelet Rich Plasma (PRP) in Total Knee Replacement: A Prospective, Randomized, Single-blind, Single-center Clinical Study to Evaluate the Effect of Platelet Rich Plasma (PRP) on Short-term Patient Outcomes Following Total Knee Replacement

NCT00826098•Exactech

View on ClinicalTrials.gov

Summary

Clinical study to evaluate the effect of platelet rich plasma (PRP), a derivative of a patient's whole blood, on short-term patient outcomes following total knee replacement (TKR).

Detailed Description

The purpose of this clinical study is to evaluate the effect of platelet rich plasma (PRP), a derivative of a patient's whole blood, on short-term patient outcomes following total knee replacement (TKR). The hypothesis is that change in short-term hemoglobin (Hgb) levels is less dramatic in patients who undergo TKR with the addition of PRP when compared to patients who undergo TKR without PRP.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patient is a male or female who is undergoing primary unilateral surgery or the first surgery of a staged bilateral total knee replacement where the second stage will be at least 6 weeks later PRP in Total Knee.
•2. Patient agrees to be blinded to their treatment group assignment.
•3. Patient is willing and able to return for follow-up over at least a six (6) week post-operative period although longer follow-up is desired
•4. Patient agrees to participate by signing an IRB approved Informed Consent Form

Exclusion Criteria

•1. Patient will have a staged bilateral total knee replacement with the second stage to be performed less than 6 weeks after the first stage surgery
•2. Patient has had previous surgery on the operative knee that will necessitate the removal of existing hardware (e.g. previous osteotomy)
•3. Patient has a known adverse reaction or sensitivity to bovine (cow) thrombin (used as part of the platelet rich plasma system) or other bovine-derived products
•4. Patient has hemoglobin \< 12.0 (males), \< 11.0 (females)
•5. Patient clinically significant anxiety disorder
•6. Patient is on therapeutic anticoagulation medication and has an INR \> 1.3
•7. Patient has a severe bleeding disorder
•8. Patient has a known addiction to drugs or alcohol, including, but not limited to: chronic daily use of narcotic medications for more than 90 days prior to surgery
•9. Patient is pregnant
•10. Patient is a prisoner
+2 more criteria

Locations (2)

Center for Joint Replacement, St. Mary's Regional Medical Center

Lewiston, Maine, United States

Peninsula Orthopedic Associates

Salisbury, Maryland, United States

Key Dates

Start Date

December 1, 2008

Primary Completion Date

June 1, 2011

Completion Date

February 1, 2013

Last Updated

September 1, 2022

Enrollment

ACTUAL participants

Conditions

OsteoarthritisInflammatory Arthritis

Interventions

Platelet Rich Plasma

BIOLOGICAL

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471

Osteoarthritis

View study

RECRUITINGPHASE1

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

NCT07351968

Moderate Pain in Knee OsteoarthritisSevere Pain in Knee Osteoarthritis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 1, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Platelet Rich Plasma (PRP) in Total Knee Replacement

Inclusion Criteria

Exclusion Criteria

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

CBD for Pain Following Orthopedic Shoulder Surgery

General vs Spinal in Total Joint Arthroplasty (TJA)

PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression